Different Ability of Clenbuterol and Salbutamol to Block Sodium Channels Predicts Their Therapeutic Use in Muscle Excitability Disorders

JEAN-FRANÇOIS DESAPHY, SABATA PIERNO, ANNAMARIA DE LUCA, PAOLA DIDONNA, and DIANA CONTE CAMERINO
Division of Pharmacology, Department of Pharmaco-Biology, University of Bari, Bari, Italy

ABSTRACT
Activation of muscle $\beta_2$-adrenergic receptors successfully counteracted sarcolemma inexcitability in patients suffering from hyperkalemic periodic paralysis (HPP), a hereditary disease caused by mutations in the gene encoding the skeletal muscle sodium channel. Looking for potential modulation of these channels by $\beta_2$-adrenergic pathway using patch-clamp technique, we found that clenbuterol blocked sodium currents ($I_{Na}$) in rat skeletal muscle fibers and in tsA201 cells transfected with the human channel isoform, whereas salbutamol did not. The effects of clenbuterol were independent of $\beta_2$-adrenergic receptor stimulation. Instead, clenbuterol structure and physicochemical characteristics as well as $I_{Na}$ blocking properties resembled those of local anesthetics, suggesting direct binding to the channels. Similar experiments with the chemically similar $\beta$-agonists propranolol and nadolol, suggested the presence of two hydroxyl groups on the aromatic moiety of the drugs as a molecular requisite for impeding sodium channel block. Importantly, clenbuterol use-dependently inhibited action potential firing in rat skeletal muscle fibers, owing to $\beta$-adrenergceptor-independent $I_{Na}$ block. From a clinical point of view, our study defines the rationale for the safe use of salbutamol in HPP patients, whereas clenbuterol may be more indicated in patients suffering from myotonic syndromes, a condition characterized by sarcolemmal overexcitability, because use-depend dent $I_{Na}$ block can inhibit abnormal runs of action potentials.
there have been no reports about the use of adrenergic agents in myotonia, most probably because sodium channel block by these drugs was not expected in skeletal muscle.

The β2-subtype is the predominant β-adrenergic receptor expressed in skeletal muscle (Liggett et al., 1988). This G protein-coupled receptor exerts its physiological function through phosphorylation of specific effectors, such as ion channels, by cyclic AMP-dependent protein kinase (PKA) (Yang and McElligott, 1989). For instance, β2-agonists were shown to increase sodium channel activity in cardiac myocytes through the classic PKA-dependent pathway but also through a membrane-delimited pathway involving direct interaction between Gαs protein and the channel (Matsuda et al., 1992; Lu et al., 1999). Nothing is known about possible similar mechanisms in the skeletal muscle.

In a previous study, we showed that two membrane-permeable analogs of cyclic AMP inhibited sodium currents (I\textsubscript{Na}) in cell-attached patches of rat skeletal muscle fibers. The effect was not mimicked by externally-applied cAMP and persisted in the presence of the PKA inhibitor N-[2-(p-bromocinnamylamino)-ethyl]-5-isouquinoline-sulfonamide (H-89), indicating that cAMP acted within the cell to block skeletal muscle sodium channels independently of PKA activation (Desaphy et al., 1998). In the present study, we sought to determine whether β2-adrenoceptor agonists might increase cyclic AMP level sufficiently to block sodium channels. We found that clenbuterol but not salbutamol inhibited I\textsubscript{Na} in rat skeletal muscle fibers or in tsA201 cells expressing the human skeletal muscle sodium (hSkM1) channels. We also showed that sodium channel block by clenbuterol can affect action potential property in skeletal muscle fibers. Those effects were independent of β2-adrenoceptor stimulation and did not involve PKA, calcium- and phospholipid-dependent protein kinase (PKC), or cyclic AMP. Thus, we propose that clenbuterol directly blocked sodium channels in a manner similar to local anesthetic drugs, and we define some structural requirements in β-agonists and antagonists for obtaining such an effect. Because of the differences in blocking muscle sodium channels, salbutamol should be safely used in periodic paralysis patients, whereas clenbuterol may be more indicated in patients suffering from myotonic syndromes.

Materials and Methods

All experiments involving animals were conducted in accordance with the Italian Guidelines for the use of laboratory animals, which conform with the European Community Directive published in 1986 (86/609/EEC).

Sodium Current Measurement in Rat Skeletal Muscle Fibers. Fibers were enzymatically dissociated from flexor digitorum brevis muscles of adult rats, and sodium currents were recorded at room temperature in the cell-attached configuration of the patch-clamp method, as described previously (Desaphy et al., 1998a). Bath solution contained 145 mM CsCl, 5 mM EGTA, 1 mM MgCl\textsubscript{2}, 10 mM HEPES, and 5 mM glucose. Pipette solution contained 120 mM CsF, 10 mM CsCl, 10 mM NaCl, 5 mM EGTA, and 5 mM HEPES, and the pH was set to 7.2 with CsOH. Peak I\textsubscript{Na} amplitudes ranging from 0.8 to 6 nA, stable series resistance errors less than 5 mV, and current run-down less than 5% within the experiment were our limiting criteria to consider the data for analysis.

Action Potential Measurement in Rat Skeletal Muscle Fibers. Action potentials were recorded in vitro in rat skeletal muscle fibers as described previously (Desaphy et al., 1998b). Briefly, the extensor digitorum longus muscles were dissected from animals under urethane anesthesia and fixed through tendons in a recording chamber containing a 95% O\textsubscript{2}/5% CO\textsubscript{2} gas mixture. Action potentials were elicited in current-clamp mode using two intracellular microelectrodes. The membrane potential was held at ~80 mV by injecting a steady current, and 100-ms depolarizing current pulses of increasing amplitude were applied up to elicit first a single action potential (threshold) and then a train of action potentials.

Drugs and Chemicals. Salbutamol, clenbuterol, DL-propranolol, 8-(4-chlorophenylthio)adenosine 3’,5’-cyclic monophosphate (CPT-CAMP), H-89, staurosporine, and okadaic acid were purchased from Sigma (Milan, Italy). QC-314 was a gift from Alomone Labs (Jerusalem, Israel). Those compounds were directly dissolved in bath or pipette solution at the desired concentration, except for H-89 and staurosporine, which were first dissolved in dimethyl sulfoxide and then diluted in recording solutions. The final concentration of dimethyl sulfoxide did not exceed 0.1% and had no effect on sodium currents.

Average data are presented as mean ± S.E.M. and statistical analysis was performed using Student’s t tests for grouped data, considering p < 0.05 as significant.

Results

Effects of β2-Agonists on Sodium Currents in Rat Skeletal Muscle Fibers. Macroscopic-current-like sodium currents were elicited in cell-attached patches of rat skeletal muscle fibers by test pulses to the potential of ~20 mV applied from a holding potential (hp) of −100 mV every 2 s (Desaphy et al., 1998a). Five minutes after seal formation, the peak I\textsubscript{Na} amplitude was sufficiently stable to allow drug testing. As shown in Fig. 1A, bath application of 900 μM salbutamol for about 5 min had no effect on I\textsubscript{Na}. In five cells, the peak I\textsubscript{Na} amplitude in the presence of salbutamol was 97.4 ± 3.0% of control. Such an effect was not distinguishable from the spontaneous run-down observed in these experimental conditions (Desaphy et al., 1998a). In contrast to salbutamol, the other β2-adrenoceptor agonist, clenbuterol (500 μM), reduced I\textsubscript{Na} to 36.8 ± 3.0% of control in four muscle fibers (Fig. 1B). The effect of clenbuterol was quite fully

...
reversible in 5 to 6 min, as shown in Fig. 1B. Normalized current-voltage relationships measured in three cells tested for clenbuterol effect are shown in Fig. 2A. Under control conditions, the current-voltage curve activated at $-60$ mV, peaked at $-20$ mV, and reached zero-current level at $+70$ mV. Clenbuterol reduced $I_{\text{Na}}$ at all voltages and did not modify the voltage at which current amplitude was maximal. The voltage dependence of the activation curve was not modified by the drug (Fig. 2B), suggesting that no change in fiber $V_m$ occurred in response to 500 $\mu$M clenbuterol. The midpoint potentials for activation were $-40.9$ mV in control and $-42.8$ mV in presence of clenbuterol. In contrast, clenbuterol shifted the voltage dependence of steady-state fast inactivation toward negative potentials, as assessed using a two-pulse protocol including a 200-ms conditioning pulse (Fig. 2C). The $8.5$ mV shift of the half-maximum inactivation potential induced by the drug was larger than the spontaneous negative shift we generally observed in cell-attached patch recordings (i.e., usually $-2$ mV in 10 min) (Desaphy et al., 1998a). The effect of clenbuterol was dose-dependent because 1500 $\mu$M clenbuterol reduced peak $I_{\text{Na}}$ to 10.7 $\pm$ 6.0% of control ($n = 4, p < 0.001$ versus. 500 $\mu$M). To further evaluate the role of PKA in current inhibition by clenbuterol, we applied the drug in presence of 10 $\mu$M H-89, a specific inhibitor of the kinase (Fig. 3). In 3 fibers, H-89 alone applied externally for 10 min had no effect on $I_{\text{Na}}$, whereas further application of 1500 $\mu$M clenbuterol still reduced peak current with potency similar to that observed in the absence of H-89.

Effects of $\beta_2$-Adrenoceptor Agonists and Antagonists on Human Skeletal Muscle Sodium Currents Expressed in tsA201 Cells. Wild-type hSkM1 channels were transiently expressed in tsA201 cells, and the resulting $I_{\text{Na}}$ were recorded with patch-clamp technique in the whole-cell configuration (Desaphy et al., 2001). Externally applied clenbuterol produced both tonic and use-dependent block of $I_{\text{Na}}$ elicited by depolarizing pulses to $-30$ mV from an $h_p$ of $-120$ mV (Fig. 4). Tonic block was assayed 3 min after drug application by measuring the reduction of $I_{\text{Na}}$ elicited at 0.1 Hz, whereas use-dependent block was further obtained by increasing stimulation frequency to 10 Hz. In the presence of 100 $\mu$M clenbuterol, $I_{\text{Na}}$ was reduced to 40% (tonic block) and 20% (10-Hz block) of control current (Fig. 4A). The inhibitory effect of clenbuterol was dose-dependent, with $IC_{50}$ values of 76 $\mu$M for tonic block and 26 $\mu$M for 10 Hz-block (Fig. 4B). The Hill coefficients calculated from the fitting functions were close to unity, thereby indicating a 1:1 stoichiometry.

In tsA201 cells, the effect of clenbuterol was not mimicked by 500 $\mu$M CPT-cAMP, a membrane-permeable analog of cyclic AMP (Fig. 5A). This contrasts with the inhibitory effect of this compound on native $I_{\text{Na}}$ recorded in skeletal muscle.
Fig. 2. Effects of clenbuterol on sodium current voltage-dependence in rat skeletal muscle fibers. A, current-voltage relationships constructed before (CTRL) and after application of 500 μM clenbuterol (CLE). The normalized current was calculated as
\[ \frac{I}{I_{\text{max}}} = \frac{g_{\text{Na}}}{g_{\text{Na,max}}} = \frac{1}{1 + \exp\left[\frac{V - V_{1/2}}{K_0}\right]} \]
where $V$ is the membrane potential, $I$ is the current, $g_{\text{Na}}$ is the sodium conductance, and $g_{\text{Na,max}}$ is the maximum conductance. The half-maximum activation potential ($V_{1/2}$) was fitted with the Boltzmann equation, $g_{\text{Na}}/g_{\text{Na,max}} = 1/(1 + \exp\left[\frac{V - V_{1/2}}{K_0}\right])$, to determine the half-maximum activation potential ($V_{1/2}$) and the slope factor ($K$). The values of $V_{1/2}$ and $K$ along with the S.E. of the fit were $-40.9 \pm 0.9$ mV and $7.7 \pm 0.8$ mV, respectively. With 500 μM clenbuterol, $V_{1/2}$ was $-42.8 \pm 0.9$ mV and $K$ was $6.5 \pm 0.8$ mV. C, availability curves for sodium current were calculated as a function of prepulse potential using
\[ \frac{g_{\text{Na}}}{g_{\text{Na,max}}} = \frac{1}{1 + \exp\left[\frac{V - V_{1/2}}{K_0}\right]} \]
where $V_{1/2}$ and $K$ are the half-maximum inactivation potential and the slope factor, respectively. The values of $V_{1/2}$ and $K$ along with the S.E. of the fit were $-89.6 \pm 0.6$ mV and $5.8 \pm 0.6$ mV in control conditions. With 500 μM clenbuterol, $V_{1/2}$ was $-98.1 \pm 0.2$ mV and $K$ was $6.1 \pm 0.2$ mV.

patches were held at $-110$ mV and depolarized every 10 s to potentials ranging from $-100$ to $+70$ mV, applied in 10-mV increments. Each data point is the mean ± S.E.M. from three patches. B, activation curves were constructed from current-voltage relationships by converting current ($I_{\text{Na}}$) to conductance ($g_{\text{Na}}$) using the equation $g_{\text{Na}} = I_{\text{Na}}/(V - E_{\text{Na}})$, where $V_{m}$ is the membrane potential and $E_{\text{Na}}$ is the equilibrium electrochemical potential for sodium ions, estimated to be $+70$ mV. Activation curves were fitted with the Boltzmann equation, $g_{\text{Na}}/g_{\text{Na,max}} = 1/(1 + \exp\left[\frac{V - V_{1/2}}{K}\right])$, to determine the half-maximum activation potential ($V_{1/2}$) and the slope factor ($K$). In control, the values of $V_{1/2}$ and $K$ along with the S.E. of the fit were $6.1 \pm 0.8$ mV and $7.7 \pm 0.8$ mV, respectively. With 500 μM clenbuterol, $V_{1/2}$ was $7.7 \pm 0.8$ mV and $K$ was $6.5 \pm 0.8$ mV. The half-maximum inactivation potential ($V_{1/2}$) and the slope factor ($K$) are illustrated in supplemental Fig. 2. The values of $V_{1/2}$ and $K$ along with the S.E. of the fit were $-89.6 \pm 0.6$ mV and $5.8 \pm 0.6$ mV in control conditions. With 500 μM clenbuterol, $V_{1/2}$ was $-98.1 \pm 0.2$ mV and $K$ was $6.1 \pm 0.2$ mV.
apply a test pulse. The recovery period should be long enough for channels to recover from inactivation but insufficient for recovery from drug block. We first measured recovery time of hSkM1 channels at −120 mV in the absence and in the presence of 100 μM clenbuterol (Fig. 6C). In the absence of clenbuterol, most of the channels (>97%) recovered from fast inactivation with a single exponential time constant (τ1 = 2.02 ± 0.06 ms). Clenbuterol introduced a second, longer exponential time constant (τ2 = 11.2 ± 3.3 s). It is clear from Fig. 6C that a recovery period of 35 ms allowed recovery from inactivation without affecting the proportion of drug-bound channels. We thus measured block of channels depolarized for 1.5 s at −70 mV, a conditioning pulse at which about 75% of the channels are inactivated, using a recovery period at −120 mV for 35 ms (Fig. 6D, inset). This protocol applied in absence of drug produced less than 5% channel block, whereas a dose-dependent block was observed in the presence of clenbuterol with an IC50 value of −30 μM (Fig. 6D). A quite similar block was obtained using a shorter conditioning pulse duration of 1 s, indicating that steady-state block of fast inactivated channels was reached (not shown). On the other hand, prolonging the conditioning pulse to 2 s produced a greater reduction of sodium current, most probably because of development of slow inactivation (not shown). To evaluate clenbuterol affinity for closed sodium channels (KcL), we constructed concentration-response curves for tonic block from an hp of −180 mV. At this potential, the entire population of hSkM1 channels is in the closed state, ready to open in

**Fig. 3.** Effects of clenbuterol on sodium currents in rat skeletal muscle fibers in presence of the cyclic AMP-dependent protein kinase inhibitor, H-89. A, ensemble average sodium currents were constructed from 10 consecutive traces elicited from −100 to −20 mV in a cell-attached patch exposed to control bath solution (CTRL, dashed line), then to 10 μM H-89, and then to 10 μM H-89 + 1500 μM clenbuterol. B, the protocol described in A was repeated in three patches and data, normalized with respect to control current, were averaged as mean ± S.E.M., and reported together with average data obtained from three patches exposed to 1500 μM clenbuterol alone.

**Fig. 4.** Dose-dependent effects of clenbuterol on human skeletal muscle sodium currents in tsA201 cells. A, whole-cell I_Na were recorded in tsA201 cells transiently transfected with the hSkM1 channel. The cells were held at −120 mV and 25-ms test pulses were applied to −30 mV. Currents were recorded under control conditions, 3 min after application of 100 μM clenbuterol at a low frequency stimulation (0.1 Hz), and during high-frequency stimulation (10 Hz). B, dose-response relationships were constructed using the protocol described in A at both 0.1 Hz (tonic block) and 10 Hz (use-dependent block). Each data point was calculated as the mean ± S.E.M. from 4 to 13 cells. The relationships were fitted with the Hill binding function, I_{drug}/I_{control} = 1/[1 + ([drug]/IC_{50})^{n_{H}}], to calculate the half-maximum inhibitory concentration (IC 50), and the logistic slope factor (n_{H}). For tonic block, the values of IC_{50} and n_{H} together with the S.E. of the fit were 76.4 ± 5.0 μM and 1.17 ± 0.09, respectively. For use-dependent block (10 Hz), IC_{50} was 25.9 ± 4.9 μM and n_{H} was 1.03 ± 0.21. Effect of 1 mM salbutamol (mean ± S.E.M., n = 3) obtained in the same experimental conditions is also reported for comparison.
response to depolarization. The \( K_R \) of clenbuterol calculated from the first-order binding function was 242 \( \mu \)M (Fig. 6D). Using the \( K_R \) value and the IC\(_{50} \) value calculated for depolarized channels, a value of \( K_R \) was estimated from the modulated receptor model equation: 

\[
\frac{1}{IC_{50}} = \frac{h}{K_R} + \frac{1 - h}{K_I}
\]

where the terms \( h \) and \( 1 - h \) are the proportions of closed and inactivated channels at the potential considered (Bean et al., 1983). The value for \( h \) in the cells used for IC\(_{50} \) determination at \(-70 \) mV was 0.25, which gives a \( K_R \) value of \(-23 \) \( \mu \)M.

Direct interaction of \( \beta \)-adrenoceptor antagonists, including propranolol, with cardiac sodium channels was proposed on the basis of their effect on the maximum upstroke velocity of action potential (Ban et al., 1985; Courtney, 1990). Although we failed to find an effect of nadolol on hSkM1 channels, the previous studies suggested that other \( \beta \)-antagonists may block \( I_{Na} \). We choose to test propranolol because chemical differences with nadolol were comparable with those between salbutamol and clenbuterol (Table 1). The external application of 1 mM propranolol greatly inhibited \( I_{Na} \), elicited to \(-30 \) mV at 0.1 Hz from an hp of \(-120 \) mV, the effect being rapid and fully reversible (Fig. 7A). Both tonic (0.1 Hz) and use-dependent (10 Hz) blocks were observed in a dose-dependent manner, with IC\(_{50} \) values of 69 and 8 \( \mu \)M, respectively (Fig. 7B).

Thus, in contrast to nadolol, propranolol did block \( I_{Na} \) and was even more potent than clenbuterol in producing use-dependent block. As already mentioned, block of sodium channels by clenbuterol and propranolol was very similar to that produced by the local anesthetic mexiletine. It is generally admitted that binding of local anesthetic drugs to their putative molecular receptors within the ion-conducting pore of skeletal muscle sodium channels requires the drugs to cross the cell membrane and to reach their binding sites from the intracellular mouth of the pore (Hille, 2001). As shown in Table 1, the presence of two hydroxyl groups on the aromatic moiety of salbutamol and nadolol greatly reduces the lipophilicity (Log P) of these drugs compared with the sodium channel blockers, suggesting that the externally applied compounds may be retained outside the cell by the plasma membrane before to reach their binding site. To verify this hypothesis, we compared the effects of salbutamol and nadolol with those of the membrane-impermeant quaternary derivative of lidocaine, QX-314 (Frazier et al., 1970). The drugs were diluted in the pipette solution, which allowed direct access to the intracellular side of the channels. Potential effect of the drugs was assayed by measuring use-dependent block of \( I_{Na} \) (Fig. 8). In the presence of 300 \( \mu \)M QX-314, use-dependent block of \( I_{Na} \) developed to \(-\)50\% of control. In contrast, neither 1 mM salbutamol nor 1 mM nadolol modified \( I_{Na} \) in response to 10-Hz stimulation.

**Effects of \( \beta_2 \)-Agonists and Antagonists on Action Potentials of Rat Skeletal Muscle Fibers.** We looked at the effect of clenbuterol on action potential behavior in rat skeletal muscle fibers by means of two intracellular microelectrodes (Desaphy et al., 1998b). The membrane potential was clamped to \(-80 \) mV before to apply depolarizing currents of increasing amplitude up to eliciting a single action potential and then a train with the maximal number of action potentials. After collection of data in control conditions, clenbuterol was applied to the muscle, and action potentials were recorded after a short delay of \(-5 \) min. At the concentration of 3 \( \mu \)M, clenbuterol had no significant effect on the single action potential but reduced by \(-\)50\% the maximum number of spikes elicited (Fig. 9B). At 30 \( \mu \)M, clenbuterol reduced the amplitude of the single action potential to \(-80\% \) of control and completely inhibited action potential firing (Fig. 9A). In the presence of 300 \( \mu \)M clenbuterol, only 3 fibers of 7 were able to elicit a single action potential, which was \(-65\% \) of control amplitude (Fig. 9C). Thus the inhibitory effect of clenbuterol on action potential was dose-dependent and use-dependent, because the drug affected the number of spikes at

---

**Fig. 5.** No role for cyclic AMP, PKA, PKC, and \( \beta \)-adrenergic receptor in the inhibitory effect of clenbuterol on human skeletal muscle sodium currents. A, whole-cell \( I_{Na} \) were recorded in tsA201 cells transiently transfected with hSkM1 channel. The cells were held at \(-120 \) mV and received a 25-ms depolarizing pulse to \(-30 \) mV every 10 s. Each bar represents the mean \pm S.E.M. from the number of cells indicated on the left of the bar of the residual current (\( I_{residual}/I_{control} \)) measured 4 to 5 min. after external application of 500 \( \mu \)M CPT-cyclic AMP, 300 nM okadaic acid, 300 nM okadaic acid + 500 \( \mu \)M CPT-cyclic AMP, and 10 \( \mu \)M H-89. B, effects of 100 \( \mu \)M clenbuterol was measured as in A in patches containing control pipette solution alone, or supplemented with 10 \( \mu \)M H-89 or 1 \( \mu \)M staurosporine, or in the presence of 1 mM external nadolol.
Clenbuterol versus Salbutamol on Skeletal Muscle Na\(^+\) Channels

State-dependent affinities of human skeletal muscle sodium channels for clenbuterol. A, voltage-dependence of \(I_{\text{Na}}\) availability in tsA201 cells transfected with hSKM1 channel. \(I_{\text{Na}}\) were evoked by a 20-ms test pulse to \(-30\) mV after 50-ms conditioning prepulses to potentials ranging from \(-150\) to \(-30\) mV in 10-mV increments. Pulses were delivered at 10-s intervals and \(h_p\) was \(-180\) mV. The peak \(I_{\text{Na}}\), recorded during the test pulse was normalized with respect to the maximal \(I_{\text{Na}}\), and means ± S.E.M. were calculated from \(n\) cells to be plotted against the prepulse potential. The relationship was determined in control conditions (CTRL) and in the presence of various concentrations of clenbuterol. Only the effects of 30 and 300 \(\mu\)M clenbuterol are shown. The relationships were fitted with the Boltzmann equation as in Fig. 2. The values of \(V_h\) and \(K\) along with the S.E. of the fit were 242.3 ± 15.0 \(\mu\)M and 1.06 ± 0.07, respectively. B, the affinity of clenbuterol for inactivated channels (\(K_i\)) was estimated by plotting the half-maximum inactivation potential \(V_{1/2}\), determined as \(h \times K\), as a function of clenbuterol concentration. Each data point was the mean ± S.E.M. from 4 to 33 cells. The relationship was fitted with the equation, \(V_{1/2} = K_{\text{CTRL}} \times \ln(1/(1 + ([\text{drug}] / K_i))) + V_{h,\text{CTRL}}\), where \(K_{\text{CTRL}}\) and \(V_{h,\text{CTRL}}\) were the values of \(K\) and \(V_h\), measured in control conditions. The values of \(K_i\) determined along with the S.E. of the fit was \(18.8 ± 2.1 \mu\)M. C, recovery from inactivation and clenbuterol block of hSKM1 channels. The cells were held at \(-120\) mV. A recovery pulse at the \(h_p\) of increasing duration was included between two test pulses at \(-30\) mV. The peak \(I_{\text{Na}}\), recorded during the second test pulse was normalized with respect to the peak \(I_{\text{Na}}\), recorded during the first test pulse and means ± S.E.M. were calculated from \(n\) cells to be plotted against the recovery time. The relationship determined in control conditions (CTRL) was fitted with a monoexponential function, \(I(t) = A_0 + A_1 \times [1 - \exp(-t/\tau)]\), whereas the relationship determined in presence of 100 \(\mu\)M clenbuterol was fitted with a two-exponential function, \(I(t) = A_0 + A_1 \times [1 - \exp(-t/\tau_1)] + A_2 \times [1 - \exp(-t/\tau_2)]\), using the value of \(\tau_1\) determined in CTRL. Fit parameters with the S.E. of the fit were \(A_0 = 0.27 ± 0.03, A_1 = 1.25 ± 0.03, \tau_1 = 2.02 ± 0.06\) ms, \(A_2 = -0.24 ± 0.02, A_3 = 1.08 ± 0.02, A_4 = 0.17 ± 0.01, \tau_2 = 11.2 ± 3.3\) ms. D, dose-response curves for depolarized and closed channels in tsA201 cells. The affinity of clenbuterol for depolarized channels was determined by eliciting \(I_{\text{Na}}\) during a test pulse at \(-30\) mV after a 1.5-s depolarization at \(-70\) mV followed by a 35-ms recovery period at \(-120\) mV. Peak \(I_{\text{Na}}\), measured in presence of clenbuterol was normalized with respect to control peak \(I_{\text{Na}}\), and each data point is the mean ± S.E.M. from at least four cells. The dose-response relationship was fitted using the Hill binding function, with \(IC_{50} = 30.1 ± 2.7 \mu\)M and \(n_H = 0.91 ± 0.07\). The affinity of clenbuterol for closed channels (\(K_i\)) was determined by holding the cells at \(-180\) mV and measuring the dose-response relationship at 0.1-Hz stimulation frequency. Each data point was calculated as the mean ± S.E.M. from 3 or 4 cells. The relationship was fitted using the Hill binding function, \(I_{\text{Na}}/I_{\text{control}} = 1/(1 + ([\text{drug}] / K_i)^{n_H})\). The values of \(K_i\) and \(n_H\) together with the S.E. of the fit were 242.3 ± 15.0 \(\mu\)M and 1.06 ± 0.07, respectively.
lower concentrations than those required to affect the single action potential. As expected from patch-clamp data, the effect of clenbuterol on action potentials was also independent of \( \beta_2 \)-adrenoceptor stimulation, because it persisted in presence of nadolol (Fig. 9D).

### Table 1

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>M.W. (free base)</th>
<th>Log P</th>
<th>pK_a</th>
<th>Ionization (mol%, pH 7.4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clenbuterol</td>
<td><img src="image" alt="Structure" /></td>
<td>277.19</td>
<td>2.612 ± 0.382</td>
<td>13.29 ± 0.20</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>Salbutamol</td>
<td><img src="image" alt="Structure" /></td>
<td>239.31</td>
<td>0.015 ± 0.301</td>
<td>9.83 ± 0.20</td>
<td>99.6</td>
</tr>
<tr>
<td>Propranolol</td>
<td><img src="image" alt="Structure" /></td>
<td>259.34</td>
<td>3.097 ± 0.193</td>
<td>13.84 ± 0.20</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>Nadolol</td>
<td><img src="image" alt="Structure" /></td>
<td>309.40</td>
<td>1.288 ± 0.344</td>
<td>13.91 ± 0.2</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>Mexiletine</td>
<td><img src="image" alt="Structure" /></td>
<td>179.26</td>
<td>2.160 ± 0.228</td>
<td>8.58 ± 0.20</td>
<td>93.4</td>
</tr>
</tbody>
</table>

### Discussion

Looking for potential modulation of skeletal muscle sodium channels by the \( \beta \)-adrenergic signaling pathway using patch-clamp technique, we observed that the \( \beta \)-adrenergic receptor...
agonist clenbuterol blocked $I_{\text{Na}}$ in native rat skeletal muscle fibers or in tsA201 cells expressing the human skeletal muscle sodium channel. This effect was independent of β-adrenoceptor modulation and rather resembled the sodium channel block by local anesthetic-like drugs, thereby suggesting direct binding of the drug to the channels. In contrast, the β-agonist salbutamol had no effect on $I_{\text{Na}}$. Such observation may have important implications for the therapeutic use of these drugs. For example, this difference between the two drugs defines the rationale for the use of salbutamol in patients suffering from periodic paralysis (sarcosomal inexcitability), whereas clenbuterol may be more indicated in patients presenting myotonic syndromes (sarcosomal overexcitability).

Although membrane-permeable analogs of cyclic AMP inhibited sodium currents in rat muscle fibers (Desaphy et al., 1998a), the nucleotide CPT-cAMP had no effect on skeletal muscle sodium channels expressed in tsA201 cells, as reported by others (Bendahhou et al., 1995). As discussed elsewhere (Desaphy et al., 1998a), such a difference suggests that the heterologous system of expression lacks a component present in skeletal muscle fibers and responsible for the effect of cAMP on sodium channels. β-Adrenergic stimulation with salbutamol was not able to increase cyclic AMP sufficiently to block sodium channels in our experimental conditions, thereby raising concerns about the physiological significance of sodium channel direct modulation by the nucleotide.

Nevertheless, the β2-agonist clenbuterol produced a rapid and reversible block of rat and human skeletal muscle sodium channels. This effect persisted in presence of PKA or PKC inhibitors, was not mimicked by salbutamol, and was not antagonized by nadolol, a β-adrenoceptor antagonist. Together, these data indicate that the inhibitory effect of clenbuterol on $I_{\text{Na}}$ was independent of β-adrenoceptor stimulation. On the other hand, the effect of clenbuterol on $I_{\text{Na}}$ was very similar to that of local anesthetic drugs that bind and block sodium channels, including a 1:1 stoichiometry, voltage- and use-dependent properties, and negative shift of voltage-dependence of sodium channel availability (Ragsdale et al., 1996). Interestingly, use-dependent block of sodium channels was also observed in cardiomyocytes (Fischer et al., 2001). Such properties have been explained by the modulated receptor hypothesis that forecasts the drug binding dependence on channel state as a result of change in receptor affinity (Hille, 2001).

Using specific voltage clamp protocols, we estimated the affinities for closed and inactivated channels to be $\sim 240$ and $\sim 20 \mu M$, respectively. For comparison, using the same expression system, a typical inactivated-channel blocker such as mexiletine showed closed-channel affinity of $\sim 800 \mu M$ and inactivated-channel affinity of $\sim 7 \mu M$ (Desaphy et al., 2001). It should be noted that higher clenbuterol concentrations were required to block $I_{\text{Na}}$ in skeletal muscle fibers to the same extent as in tsA201 cells, although voltage-clamp protocols should be more favorable to block in the native system, where less negative $h_p$ and higher frequency of stimulation were used. Hypothetical causes for such include differences in receptor affinity between the rat and the human sodium channels or differences in intracellular medium (for muscle fiber) and experimental solutions between the two systems. Importantly, inhibition of muscle action potential firing was obtained in more physiologic conditions (e.g., $h_p = -80 \text{ mV}$) with clenbuterol concentrations lower than those required to block $I_{\text{Na}}$ in cell-attached patches of muscle fibers, as described below.

The putative molecular receptor for local anesthetic-like drugs includes amino acids of the S6 segments of domains I, III, and IV that face the ion-conducting pore of voltage-gated sodium channel α-subunits (Ragsdale et al., 1994; Nau et al., 1999; Wang et al., 2000; Yarov-Yarovoy et al., 2001; 2002). It was proposed that the two pharmacophore moieties of many local anesthetics, constituted of an uncharged aromatic ring and a charged tertiary amine, may bind to amino acid side chains through hydrophobic and cation-r interactions, respectively (Ragsdale et al., 1994). Interestingly, clenbuterol also presents a hydrophobic ring at one extreme and an amine group at the other end (Table 1). The ring confers to clenbuterol a lipophilicity comparable with that of mexiletine, as evidenced by the $\log P$ value. Moreover, the $pK_a$ of clenbuterol is very similar to that of mexiletine, and drug molecules are mostly protonated at physiological pH. Thus, molecular structure, physicochemical properties, and sodium channel block feature of clenbuterol strongly suggest that the drug binds to the sodium channel at the local anesthetic receptor.

It has long been hypothesized that β-adrenoceptor antagonists may exert part of their antiarrhythmic action by blocking directly cardiac sodium channels. Indeed direct interaction of β-adrenoceptor antagonists, including propranolol, with sodium channels was proposed on the basis of $^{22}\text{Na}^+$ uptake measure in rat brain membrane (Matthews and Baker, 1982), and cardiac action potential modulation (Ban et al., 1982; Courtney, 1990), and $^3\text{H}$-batrachotoxin-A 20-alpha-benzoate binding studies to rat cerebrocortical synaptosomes.

**Fig. 8.** Development of use-dependent block after internal diffusion of control pipette solution (CTRL, plain line), or pipette solution supplemented with 1 mM nadolol (△), 1 mM salbutamol (○), or 300 μM QX-314 (●). The hSkM1-transfected tsA201 cells were held at $-120 \text{ mV}$ and received a 25-ms depolarizing pulse to $-30 \text{ mV}$ every 10 s to elicit $I_{\text{Na}}$. This protocol was applied about 5 min after achieving whole-cell configuration to allow pipette solution to diffuse well within the cell. Peak $I_{\text{Na}}$ measured at each test pulse was normalized with respect to the first pulse $I_{\text{Na}}$. Each data point is the mean ± S.E.M. from five cells in each condition. The S.E.M. bars are omitted for CTRL, nadolol, and salbutamol to improve clarity.
The present study confirms inhibition of \( I_{\text{Na}} \) by propranolol using patch clamp technique. As clenbuterol, propranolol blocked human sodium channels in a use-dependent manner and shifted negatively the voltage dependence of channel availability (not shown). The IC\(_{50}\) value for tonic block at a hp of \(-120\) mV was similar to that of clenbuterol, whereas use-dependent block was three-fold more pronounced with the \( \beta \)-antagonist. The structure of propranolol that includes a strongly lipophilic naphthalene moiety and a protonated amine fulfills the general structural requirements for sodium channel binding and block by local anesthetic-like drugs, as described above for clenbuterol.

Fig. 9. Effects of clenbuterol on action potentials in rat skeletal muscle fibers. Action potentials were recorded in rat muscle fibers using two-microelectrode current clamp method. A, representative single action potentials elicited by threshold current in absence (CTRL) and presence of 30 \( \mu \)M clenbuterol (CLE). B, representative train of action potentials elicited by subthreshold current in absence (CTRL) and presence of 3 \( \mu \)M clenbuterol (CLE). C, amplitude of single action potential elicited as in A (left) and maximum number of spikes obtained as in B (right), in the absence or presence of 3, 30, and 300 \( \mu \)M clenbuterol, are reported as means \( \pm \) S.E.M. from \( n \) fibers of \( N \) rats, indicated in parenthesis as (\( N/n \)). D, amplitude of single action potential elicited as in A (left) and maximum number of spikes obtained as in B (right), were measured in control conditions (CTRL), in presence of 300 \( \mu \)M nadolol (NADO), and then in presence of 300 \( \mu \)M nadolol and 30 \( \mu \)M clenbuterol (NADO + CLE) and reported as percentage of control. For comparison, effect of 30 \( \mu \)M clenbuterol alone (CLE) is also reported. Each bar is the mean \( \pm \) S.E.M from \( n \) fibers of \( N \) rats, indicated as (\( N/n \)). Statistical differences were assessed with unpaired Student’s \( t \) test (*, \( p < 0.001 \); **, \( p < 0.005 \)).
In contrast to clenbuterol and propranolol, salbutamol and nadolol had no effect on $I_{Na}$. From Table 1, it seems that the two inactive compounds are characterized by the presence of two hydroxyl groups on the aromatic moiety that render them far less lipophilic compared with clenbuterol and propranolol. It can be hypothesized that the hydroxyl groups may impede the hydrophobic interaction between the aromatic moiety and the local anesthetic receptor. Interestingly, such a mechanism of action potential of clenbuterol in the myotonic syndromes. In particular, because of the possibility of combining antimyotonic activity with its well known anabolic action, clenbuterol might be remarkably indicated in the treatment of myotonic dystrophy, the most common hereditary disease of skeletal muscle, characterized by muscle wasting together with permanent or fluctuans myotonia (Meola, 2002). On the other hand, because sodium channel block may accentuate paroxysm, clenbuterol should not be administered to patients with HFP, whereas other $\beta_2$-agonists, such as salbutamol, have proven to be beneficial in those patients, most probably because $\beta_2$-adrenoceptor stimulation activates the Na,K-ATPase and consequently hyperpolarizes the muscle fiber (Wang and Claussen, 1976; Claussen et al., 1993; Hanna et al., 1998).

Acknowledgments
We thank Prof. Alfred L. George for providing the hSkM1 and CD8 plasmds, Prof. Giovanni Lentini for helpful discussion, and Luciano Corropoli for technical assistance.

References

Address correspondence to: Diana Conte Camerino, Division of Pharmacology, Department of Pharmaco-Biology, University of Bari, via Orabona 4-campus, 70125 Bari, Italy. E-mail: conte@farmbiol.uniba.it